Astellas Terminates Agreement on Acute Heart Failure Agent Carperitide

Today announced that its US affiliate, Astellas US LLC, has terminated its license agreement with Daiichi Asubio Pharma Co., Ltd. regarding North

TOKYO, Japan | Jan 11, 2007 | Astellas Pharma Inc. (headquarters: Tokyo, president and CEO: Masafumi Nogimori, hereinafter “Astellas”) today announced that its US affiliate, Astellas US LLC, has terminated its license agreement with Daiichi Asubio Pharma Co., Ltd. (headquarters: Tokyo, president and CEO: Seiichi Yokoyama, hereinafter “Daiichi Asubio Pharma”) regarding North

American and European Union rights to carperitide for the treatment of acute heart failure. Astellas US LLC’s predecessor, Fujisawa Healthcare, Inc. and Daiichi Asubio Pharma’s predecessor, Daiichi Suntory Pharma Co., Ltd. executed the license agreement in May, 2003. Astellas’ affiliate in the US had conducted some clinical trials using carperitide in the United States but after reassessing competitive circumstances and market potential, decided to discontinue carperitide development. As a result of this decision, both parties have agreed to terminate the license agreement.

Astellas recognizes cardiovascular disorders as an important category through the development of pipeline compounds and the marketing of such products as Adenoscan®, a pharmacologic stress agent in pharmaceutical stress testing; Vaprisol® for euvolemic hyponatremia; and Adenocard®, an anti-arrhythmic agent in the United States.

Contacts for inquiries or additional information
Astellas Pharma Inc.
Corporate Communications
Tel: +81-3-3244-3201 Fax: +81-3-5201-7473
http://www.astellas.com


SOURCE: Astellas Pharma Inc.

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top